@dolcevita, its not that hard to research, if your going to quote from WHO, should have been easy for you to provide this...
WHO Situation report 13 - https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200202-sitrep-13-ncov-v3.pdf?sfvrsn=195f4010_2
TECHNICAL FOCUS: Risk communication and community engagement Managing the 2019-nCoV ‘infodemic’ The 2019-nCoV outbreak and response has been accompanied by a massive ‘infodemic’ - an over-abundance of information – some accurate and some not – that makes it hard for people to find trustworthy sources and reliable guidance when they need it. Due to the high demand for timely and trustworthy information about 2019-nCoV, WHO technical risk communication and social media teams have been working closely to track and respond to myths and rumours.
eg, don't instantly believe social media and news outlets that are over sensationalising it because its the story of the moment.
RECOMMENDATIONS AND ADVICE FOR THE PUBLIC During previous outbreaks due to other coronavirus (Middle-East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), human-to-human transmission occurred through droplets, contact and fomites, suggesting that the transmission mode of the 2019-nCoV can be similar. The basic principles to reduce the general risk of transmission of acute respiratory infections include the following:
• Avoiding close contact with people suffering from acute respiratory infections.
• Frequent hand-washing, especially after direct contact with ill people or their environment.
• Avoiding unprotected contact with farm or wild animals.
• People with symptoms of acute respiratory infection should practice cough etiquette (maintain distance, cover coughs and sneezes with disposable tissues or clothing, and wash hands).
• Within healthcare facilities, enhance standard infection prevention and control practices in hospitals, especially in emergency departments. WHO does not recommend any specific health measures for travellers. In case of symptoms suggestive of respiratory illness either during or after travel, travellers are encouraged to seek medical attention and share their travel history with their healthcare provider.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA, page-100
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.38 |
Change
0.130(10.4%) |
Mkt cap ! $1.421B |
Open | High | Low | Value | Volume |
$1.27 | $1.40 | $1.27 | $4.989M | 3.735M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 18556 | $1.37 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.38 | 8654 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 41900 | 1.340 |
6 | 46345 | 1.335 |
8 | 55174 | 1.330 |
7 | 99240 | 1.325 |
9 | 67253 | 1.320 |
Price($) | Vol. | No. |
---|---|---|
1.350 | 28378 | 7 |
1.355 | 42616 | 7 |
1.360 | 92858 | 10 |
1.365 | 90184 | 8 |
1.370 | 20363 | 6 |
Last trade - 10.44am 03/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |